Company / Working Capital per Share
CytomX Therapeutics, Inc. Working Capital per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital per Share
$0.71
FY2025
5-year range
$0.27 / $3.12
FY2021-FY2025
Trend
+162.4%
vs FY2024
Sector context
#188 of 210
Health Care
What the data says
Among 210 Health Care companies, CytomX Therapeutics, Inc. is in the bottom 10% for working capital per share. Working Capital per Share returned to growth in FY2025 after 4 years of decline, reaching $0.71.
Based on SEC 10-K filings.
0.71 in FY2025 with a 5-year CAGR of -32.1%.
Improved from $0.40 to $0.71 over the past 2 years.
Health Care sector context is included.
Working Capital per Share over time
Growth rates
- 3-Year CAGR
- -17.9%
- 5-Year CAGR
- -32.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 10% in Health CareTop 90% of 210This company $0.71 Sector average $146.86
▼
-99.5% below sector average
Key checks
Key Insights
- In FY2025, working capital per share increased 162.4% year-over-year.
- Ranks #188 out of 210 companies in the Health Care sector.
- Peak working capital per share was recorded in FY2017.
- Lowest working capital per share in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.68 (distress zone, below 1.8 threshold)
- Strong profit margin: 23.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working Capital per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.71 | +162.4% |
| FY2024 | $0.27 | -33.0% |
| FY2023 | $0.40 | -68.5% |
| FY2022 | $1.28 | -59.1% |
| FY2021 | $3.12 | -36.3% |
| FY2020 | $4.90 | +2.5% |
| FY2019 | $4.78 | -38.0% |
| FY2018 | $7.71 | -9.4% |
| FY2017 | $8.51 | +103.8% |
| FY2016 | $4.18 | -97.6% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026